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ABSTRACT: Defective mitochondrial proteins are emerg-
ing as major contributors to human disease. Nicotinamide
nucleotide transhydrogenase (NNT), a widely expressed
mitochondrial protein, has a crucial role in the defence
against oxidative stress. NNT variations have recently
been reported in patients with familial glucocorticoid de-
ficiency (FGD) and in patients with heart failure. More-
over, knockout animal models suggest that NNT has a
major role in diabetes mellitus and obesity. In this study,
we used experimental structures of bacterial transhydro-
genases to generate a structural model of human NNT
(H-NNT). Structure-based analysis allowed the identifi-
cation of H-NNT residues forming the NAD binding site,
the proton canal and the large interaction site on the H-
NNT dimer. In addition, we were able to identify key
motifs that allow conformational changes adopted by do-
main III in relation to its functional status, such as the
flexible linker between domains II and III and the salt
bridge formed by H-NNT Arg882 and Asp830. More-
over, integration of sequence and structure data allowed
us to study the structural and functional effect of delete-
rious amino acid substitutions causing FGD and left ven-
tricular non-compaction cardiomyopathy. In conclusion,
interpretation of the function–structure relationship of H-
NNT contributes to our understanding of mitochondrial
disorders.
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Introduction
Nicotinamide nucleotide transhydrogenase (NNT, MIM
#607878), a widely expressed integral protein of the inner mito-
chondrial membrane [Arkblad et al., 2002], catalyzes the transhy-
drogenation between NADH and NADP+ and the proton translo-
cation across the mitochondrial membrane. Because of its role in
maintaining the redox balance, NNT has a crucial role in defence
against oxidative stress [Circu and Aw 2010]. Variations in NNT
have recently been reported in patients with familial glucocorticoid
deficiency (FGD, MIM#614736), a rare, life-threatening condition
[Meimaridou et al., 2012; Yamaguchi et al., 2013; Novoselova et al.,
2015] and in one patient with combined adrenal failure and tes-
ticular adrenal rest tumor [Hershkovitz et al., 2015]. Moreover, a
reduction in human NNT (H-NNT) activity has been reported in
the heart of patients with heart failure [Sheeran et al., 2010; Bain-
bridge et al., 2015] and knockout animal models suggest a role for
Nnt in impaired insulin secretion, diabetes mellitus, and obesity
[Freeman et al., 2006; Rydstro¨m 2006; Andrikopoulos 2010; Heiker
et al., 2013]. Studies inmice withNnt deletion and acute pulmonary
infection by Streptococcus pneumoniae suggest that Nnt can also be a
regulator of the macrophage-mediated inflammatory response and
the defence against pathogens [Ripoll et al., 2012].
The increase in reactive oxygen species resulting from perturba-
tion of the redox balance (oxidative stress) can lead to cell damage
and apoptosis [Circu andAw 2010], which contribute to aging, neu-
rological disorders [Uttara et al., 2009], and cancer [Reuter et al.,
2010]. NNT is, thus, a strong candidate in the search for novel genes
involved in the pathogenesis of the above conditions. Several novel
genetic variations are likely to be identified in NNT in the near fu-
ture because of sequencing efforts such as the 100Kgenomes project.
Understanding the structure and function of NNT is, therefore, of
paramount importance in the prioritization and characterization of
novel NNT genetic variations.
NNT exists as a homodimer [Pedersen et al., 2008]. Each
monomeric NNT is characterized by three domains: the NAD(H)
binding domain (domain I), the transmembrane domain (domain
II), which is responsible for anchoring NNT to the mitochondrial
inner membrane and for proton translocation and the NADP(H)
binding domain (domain III). Domain I and III are located on
the matrix side in mitochondria and on the cytoplasmic side in
bacteria [Cotton et al., 2001]. Hydride transfer between NAD(H)
and NADP(H) occurs at the interface between domains I and III
and is coupled with proton translocation across the proton canal
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Table 1. PDB Files used to Generate the H-NNT Structural Model
PDB file Ligand Method Resolution Seq Id % NNT domain Organism
2bru NAD, NADP NMR – 56 I, I-I, I-III E. coli
4izh Glycerol X-ray 1.8 A˚ 41 I T. thermophilus
4o9p (chains C-D) – X-ray 2.89 A˚ 31 II T. thermophilus
1djl NADP, sulfate ion, glycerol X-ray 2.0 A˚ 100 III Homo sapiens
4o9u NAD, NADP X-ray 6.93 A˚ 33 Holo-NNT T. thermophilus
Seq id %, percentage of sequence identity to H-NNT amino acid sequence; NAD, nicotinamide-adenine-dinucleotide; NADP, nicotinamide-adenine-dinucleotide phosphate.
located in domain II [reviewed in [Pedersen et al., 2008]]. The crys-
tal structure of domain I, with and without NAD(H), has been
determined in Rhodospirillum rubrum [Prasad et al., 2002] and Es-
cherichia coli [Johansson et al., 2005], whereas that of domain III in
bovine [Prasad et al., 1999] and human transhydrogenase [White
et al., 2000]. Moreover, a solved structure of domain I–III com-
plex was determined in R. rubrum [Cotton et al., 2001]. A recent
breakthrough has been the crystallized 6.9 A˚ structure of the Ther-
mus thermophilus transhydrogenase (Tt-NNT) homodimer [Leung
et al., 2015], which allowed clarification of how the three domains
are positioned in relation to one another. Moreover, it showed the
180° flipping of domain III relative to domain I, which allows the
NAD(H) and NADP(H) binding sites to come in close contact and
exchange hydride.
We present a structural model of the H-NNT protein and a struc-
tural analysis of NNT deleterious amino acid substitutions causing
FGD. Moreover, we present the results of a comparative sequence
analysis among different species and structural annotation of evo-
lutionary conserved motifs for the purpose of identifying residues,
which are unlikely to tolerate substitutions.
Materials and Methods
The amino acid sequence of H-NNT (UniProt Identification
Code (ID) Q13423, GenBank: AAC51914.1), E. coli (UniProt IDs
P07001 and P0AB67, GenBank: CAB37089.1 and CAB37090.1, re-
spectively) and T. thermophilus (UniProt IDs Q72GR8, Q72GR9,
Q72GS0, GenBank: AAS82122.1, AAS82121.1, AAS82120.1, respec-
tively) were retrieved from UniProt [UniProt Consortium 2015].
The amino acid numbering system is based on the initiation codon
as codon 1, as per the HGVS recommendations.
A structural model of NNT domains was generated using Phyre2
prediction program [Kelley et al., 2015]. Although the structure
of the holo Tt-NNT was available [Leung et al., 2015], its resolu-
tion is very low and not appropriate for homology modeling. We,
therefore, first modeled individual domains using the best template
structures available.Modeling of individual domainswas performed
automatically using Phyre2 [Kelley et al., 2015], as detailed in Supp.
Methods. A list of all templates used to generate the H-NNT model
is presented in Table 1. The amino acid percentage relative surface
accessibility area (rASA) was calculated by dividing its total surface
area with that in the extended conformation (φ =  = 180°) of the
Gly–X–Gly tripeptide. Residues were defined as solvent accessible if
rASA > 7%, otherwise buried [Worth and Blundell 2010]. Residues
were assigned to interface when the distance between at least one
atom on two different interacting proteins was within 5 A˚. Interface
residues were defined as “interface core” when becoming buried
upon interaction, otherwise they were “interface rim” [Chakrabarti
and Janin 2002]. Disordered regions were predicted using Diso-
pred2 prediction program [Ward et al., 2004]. 3DLigandSite was
used to predict residues interacting with dinucleotide coenzymes
[Wass et al., 2010].
For structural analysis, the following structural elements were
considered: (i) salt bridges, defined as at least one pair of atoms
on oppositely charge groups within a 4.5 A˚ distance; (ii) hydrogen
bonds (H-bond), defined as a donor–acceptor distance2.5 A˚ and
an angle at the acceptor 90°; (iii) pi–pi stacking, defined as an
interaction between two aromatic rings, where the maximum dis-
tance between the ring centroids is <4.4 A˚ and the angle between
ring planes <30° (face-to-face) or the distance is <5.5 A˚ and >60°
angle <120° (edge-to-face); (iv) disulfide bridge (S-S bridge) de-
fined as the side chains of two cysteines at a 3.0 A˚ distance. Pairs
of cysteines at a greater distance were also considered as potentially
forming an S-S bridge when their Cα-Cα distance was <10 A˚. We
used Cα distance to allow for errors in side-chain placement and a
relatively high threshold to accommodate possible deviation of the
backbone from the native.
The NNT electrostatic potential was calculated using PBEQ pro-
gram [Jo et al., 2008], which computes the protein electrostatic
potential by solving the Poisson–Boltzmann equation. The pres-
ence of a signal peptide was investigated using SignalP 4.1 [Petersen
et al., 2011]. The presence of amitochondrial targeting sequencewas
predicted using TargetP 1.1 [Emanuelsson et al., 2007] and Predo-
tar [Small et al., 2004]. Three variant phenotype prediction servers
SIFT [Kumar et al., 2009], Polyphen2 [Adzhubei et al., 2010] and
Suspect [Yates et al., 2014] were used to assess the damaging na-
ture of single amino acid variations (SAVs). The logo was generated
using Weblogo [Crooks et al., 2004].
The amino acid sequences for NNT homologs were retrieved
from Uniprot and Ensembl. Homologs were selected among those
with high-coverage sequencing and complete genome assembly,
from species spanning a broad evolutionary distance. For bacte-
rial genomes, the sequences of the different elements of the operons
were concatenated. The sequences were aligned using the G-INS-i
algorithm implemented in theMAFFTpackage (global-global align-
ment) [Katoh and Standley 2013]. The alignment robustness was
checked using GUIDANCE2 [Penn et al., 2010]. Amino-acid con-
servation profiles were analyzed using ConSurf [Ashkenazy et al.,
2010]. The sequence alignment was generated using ESPript 3.0
[Robert and Gouet 2014]
Results
Overview of Human NNT
H-NNT is encoded by a single gene, whereas bacteria transhy-
drogenases are encoded by two (E. coli, UniProt IDs P07001 and
P0AB67, GenBank: CAB37089.1 and CAB37090.1, respectively)
or three genes (T. thermophilus, UniProt IDs Q72GR8, Q72GR9,
Q72GS0, GenBank: AAS82122.1, AAS82121.1, AAS82120.1, respec-
tively). Nevertheless, the structural organization of theNNTprotein
is similar across different species, with domain III always at the C-
terminal part of the protein [Cotton et al., 2001; Leung et al., 2015].
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Figure 1. A: Domain organization of H-NNT. Domains are color-coded (domain I in yellow, domain II in gray and domain III in green). The 14 TMs
of domain II are also indicated. The position of deleterious amino acid substitutions identified in H-NNT and described in this study is presented. The
protein regions for which an experimental or homology-derived structure is available (structural coverage) are also shown. B: Three-dimensional
model of H-NNT homodimer (monomer A and monomer B) inserted in the inner mitochondrial membrane. The reaction catalyzed by NNT is also
presented. On the right, domain III (in green) is in the up-face orientation with the NADP(H) binding site (in magenta) oriented toward domain I (in
yellow) and interacting with the NAD(H) binding site (in blue). On the left, domain III (in green) is in the face-down orientation, with the NADP(H)
binding site (in magenta) facing away from the NAD(H) binding site (in blue) and in close proximity to domain II (in gray). H-NNT dimeric model is
based on Tt-NNT (PDB 4O9U).
H-NNT is comprised of three domains (Fig. 1]: the N-terminal
domain (domain I: residues 1–474) located in the mitochondrial
matrix and containing a predicted mitochondrial targeting peptide
(1–39 aa) and the NAD binding site; a transmembrane domain
(domain II: residues 475–880), which spans the inner mitochon-
drial membrane and a C-terminal domain (domain III: residues
881–1086), which contains the NADP binding site.
The structural model of NNT was built by template-based mod-
eling. A total of 924 (85%) of H-NNT residues were modeled (for
62 of these residues no coordinates were found in the template
and their predicted secondary structure was automatically gener-
ated by Phyre2). For 162 residues, no template was available and
no secondary structure was generated. Forty-one of these residues
were predicted disordered (the detailed sequence-structure align-
ment is presented in Supp. Table S1). Each of the three domains was
modeled using a different structural template (detailed in Table 1]
and the structure of the individual domains is discussed separately
(a multiple sequence alignment (MSA), between NNT and its close
homologues is presented in Supp. Fig. S1 and the degree of conserva-
tion of the amino-acid sites between NNT and its close homologues
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Figure 2. NAD binding site in H-NNT domain I. The 3D model structure of H-NNT was used to identify residues likely to participate in NAD
binding.
is presented in Supp. Table S2). The Phyre2 confidence score, which
reflects the probability that the chosen template is correct, was 100%
in all cases.
NNT domain I
The 3D structure of domain I (residues Val59-Lys442) was mod-
eled using the NAD transhydrogenase experimental structures of E.
coli (PDB: 2bru, sequence identity with human sequence = 56%).
This was preferred to that of T. thermophilus (PDB: 4izh, sequence
identity = 41%) because of the higher sequence identity to H-NNT.
The quality of themodelwas overall good (PROCHECKRamachan-
dran statistics: 1% in disallowed regions, 85% residues in favored
regions and 14% in additionally allowed regions; ProSA Z-score
–8.48, which is within the range of scores typically found for na-
tive proteins of similar size; Supp. Fig. S2). Superposition between
H-NNT domain I and E. coli NNT template demonstrated that the
two structures have the same overall conformation with minimal
structural differences (r.m.s.d. = 0.60 A˚).
Several salt bridges, which are likely to contribute to structural
stabilization of domain I, were identified: Glu64-Lys127, Lys127-
Glu141, and Asp312-Lys338, which are also present in the E. coli
template structure and Arg254-Glu310 and His210-Glu361, which
appear to be specific to H-NNT. A structural analysis demonstrated
the presence of a beta-alpha-beta fold (Rossmann fold), which
is typically present in domains binding dinucleotide coenzymes
[Kutzenko et al., 1998]. In particular, residues 234–239 formed the
consensus sequence Gly-X-Gly-X-X-Gly located at the beta-alpha
junction of the beta-alpha-beta fold [Hanukoglu 2015].
NAD was modeled with H-NNT domain I using 3Dligandsite
and residues that are predicted to interact with NAD are presented
in Figure 2 and Supp. Figure S3. The conformational changes oc-
curring at the NAD binding site (as described below), do not allow
excluding that additional H-NNT residues may participate in NAD
binding. Amino acids 319–323 (residues LIPGK, which are located
within a loop) and Arg182 are conserved between human and E.
coli, as shown by sequence alignment (Supp. Figures S4A and S4B).
Studies in E. coli show that these residues are crucial for NNT func-
tion. Comparison of experimental structures of E. coli domain I,
determined both in the absence and presence of NAD and NADH,
demonstrate that the side chains of Arg120, Leu257, and Pro262
(corresponding to Arg182, Leu319, and Pro321 in H-NNT, respec-
tively) adopt different conformations according to the presence or
absence of NAD and NADH. When domain I is bound to NAD, the
side chain of Arg120 points toward NAD and makes strong inter-
action with it, whereas in the Apo Domain I (with no substrate)
and in the Domain I-NADH complex, the side chain points in the
opposite direction, away fromNADH. Similarly, Leu257 and Pro262
can adopt at least three different conformations, according to pres-
ence of NAD or NADH [Johansson et al., 2005]. Residues 181–194
form the so-called RQD loop. Residues Arg182, Val183, Thr184, and
Gln187 are evolutionarily conserved and are predicted to interact
withNAD (Fig. 2). In addition, Asp190 is located at 3.8 A˚ fromNAD
C4 atom and could participate in NAD binding. Ser193 is also an
invariable residue and is part of the enzyme catalytic site, which also
involves the invariable Arg182, Gln187, and Asp190 (Supp. Fig. S5).
Residues 211–229 are arranged in a beta hairpin fold. Residues
Phe211 and Phe215 are evolutionarily conserved, as demonstrated
by the MSA and are predicted to form stacking interactions, thus,
stabilizing the beta hairpin structure. The beta hairpin fold is a
conserved structural feature of NNT as it is present in bacterial
transhydrogenases. This suggests that the beta hairpin fold is in-
volved in human NNT catalytic activity, similar to what is observed
in bacteria [Johansson et al., 2005]. In addition, the beta hairpin
fold participates in domain I homodimerization, as detailed below.
The last 35 amino acids of domain I (residues 437–472) are pre-
dicted to be disordered and no alpha helices or beta strands regions
were predicted. This short polypeptide is likely to represent a linker
between domains I and II. The linker is likely to be flexible, with the
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exception of its initial sequence (residues Pro437, Arg438, Pro439,
Thr440, and Pro441), which is predicted to have a rigid structure.
The MSA showed that residues P437, A438, and P439 are highly
conserved among different species.
NNT domain II
Different species have different numbers of the transmembrane
α helices (TM) in the transmembrane domain (domain II): 14
TMs in H-NNT, 13 TMs in E. coli, and 12 TMs in Tt-NNT. H-NNT
domain II (residues Leu496–Met581 corresponding to TMs 2–4 and
residues Asn618–Ile888 corresponding to TMs 6–14) was modeled
using theTt-NNT structure (PDB4o9p, sequence identity to human
protein = 33%; r.m.s.d. between template and model = 0.63 A˚).
This allowed modeling of 349 out of 405 (86%) residues. TM1 and
TM5 were not modeled due to the presence of only twelve TM
helices in Tt-NNT (a cartoon of H-NNT domain II is presented in
Supp. Fig. S6). The model accuracy was overall good (PROCHECK:
Ramachandran statistics: 0% in disallowed regions, 94% residues
in favored regions and 5% in allowed regions; ProSA Z-score –4.89,
which iswithin the range of scores typically found for native proteins
of similar size; see Supp. Fig. S7).
One of the most important features of domain II is the presence
of the proton translocation canal. In T. thermophilus, the proton
canal is formed by TM helices 2, 3, 7, 8, 11, 12, and has a hexagonal
topology [Leung et al., 2015]. The same hexagonal topology is seen
in the H-NNT proton translocation canal, which is formed by TM
helices 3, 4, 9, 10, 13, and 14.
Mutagenesis studies in E. coli have identified residues within the
proton canal that are essential for proton translocation through the
mitochondrial membrane. Structural alignment between the hu-
man model and the bacterial templates allowed mapping and iden-
tificationof these functionally and structurally important residues in
H-NNT. Residues His707 (in TM9), Ser756 (in TM10), and Asn839
(in TM13) form part of the canal’s interior face. They are highly
conserved and correspond to residues His89, Ser139 and Asn222 in
E. coli, respectively. Mutational studies in E. coli showed that these
residues are essential for proton translocation activity [Holmberg
et al., 1994; Bragg and Hou 2001]. This crucial function is likely to
be retained by the corresponding residues in H-NNT. Alignment of
TM helices forming the proton canal showed a high level of con-
servation at sequence and structural level. The conserved His524
(H450 in E. coli) is part of the loop between TM2 and TM3, which
is located in the mitochondrial matrix. In E. coli, its substitution
results in a markedly reduced proton translocation activity [Holm-
berg et al., 1994]. An additional residue, which, when substituted,
inhibits the enzyme function possibly by altering its structure, is the
conserved Met876 (Met259 in the beta subunit of E. coli) [Karlsson
et al., 2003]. Although the majority of substitutions result in an in-
active enzyme, it is worth noticing that substitution of the conserved
Ser867, Ser868, and Ser873 (Ser250, Ser251, and Ser256 in E. coli,
respectively) located in TM14 have been shown to enhance NNT
activity possibly through an allosteric effect mediated by TM14 on
NADP binding [Yamaguchi and Stout 2003; Karlsson et al., 2003].
Inhibition of NNT function can also result from amino acid
substitutions that affect the tight packing of domain II alpha he-
lices, which is driven by the interaction between the side chains of
glycine and isoleucine/valine (the so called “groove-ridge system”).
Because of its special role in the packing of helices, glycine substi-
tution with any other amino acid can result in profound structural
modification and NNT malfunction. Accordingly, in vitro stud-
ies have demonstrated that substitution of the invariant Gly711
(TM9), Gly749 (TM10), Gly755 (TM10), Gly843 (TM13), Gly850
(TM13) impairs proton translocation and transhydrogenation ac-
tivity (Gly95,Gly132,Gly138,Gly226,Gly233 inE. coli, respectively)
[Yamaguchi andStout 2003].Moreover, substitutionof the invariant
Gly862, Gly866, and Gly869 (Gly245, Gly249, and Gly252 in beta
E. coli, respectively), which form the last TM helix (TM14, which
completes the proton translocation canal hexagonal structure), has
been shown to reduce NNT function [Yamaguchi and Stout 2003;
Karlsson et al., 2003], possibly through disruption of the groove-
ridge system, which contributes to tight packing of TM14 against
TM13 in human and bacterial transhydrogenases.
A partially disordered linker connects domain II and III (residues
880–912, of which residues 893–912 are predicted to be disordered).
The disordered nature of the linker allows the 180° flip of domain III
relative to domain I and II described by Leung et al. (2015). Of great
interest are the highly conserved residues Asp830 (located in the
cytoplasmic loop of domain II, between TMs 12–13, at the opening
of the proton canal toward the mitochondrial matrix) and Arg882
(located within the linker). These two residues form a salt bridge,
which is a conserved feature across species (a salt bridge is formed
by equivalent residues Asp202 and Arg254 in Tt-NNT [Leung et al.,
2015] and βAsp213-βArg265 in E. coli [Althage et al., 2001]. In line
with the conformational changes adopted by domain III in rela-
tion to its functional status, residues Asp830 and Arg882 have been
shown to interact in the absence of NADP, but not in its presence
[Althage et al., 2001]. Moreover, substitution of equivalent residues
in E. coli alters NNT proton translocation activity [Yamaguchi and
Hatefi 1995]. The holo Tt-NNT solved with NADP [Leung et al.,
2015] shows that the salt bridge formed by these two residues is
adjacent to the entrance of the proton canal and in the face-down
conformation (which is competent for proton translocation), the
NADP binding site in domain III comes in close contact with the
salt bridge and the proton canal. Residues Asp830 and Arg882 in
the H-NNT are likely to have the same crucial functional and struc-
tural role as described for the equivalent residues in Tt-NNT and
E. coli.
NNT domain III
TheNNTdomain III (residues Pro902–Ser1083) bound toNADP
was crystallized from human heart mitochondria in 2000 (PDB id:
1djl) [Peake et al., 2000; White et al., 2000] and an extensive struc-
tural analysis of this domain is described by White et al. (2000). We
will therefore limit our analysis to the identification of structurally
and/or functionally important residues in this domain.
Five salt bridges can be identified in this domain and are likely
to help stabilize its structure (Asp915–Lys1079, His995–Asp996,
Glu1018–Lys1059, Glu1031–Lys1034, Lys1070–Asp1074). Struc-
turally, the NADP binding site is characterized by the Rossmann
fold and residues 932–937 form the consensus sequence Gly-X-Gly-
X-X-Ala/Val. The residues forming the NADP cleft, which makes
contact with NADP, are shown in Figure 3.
H-NNT dimeric structure and open challenges
NNT assembles in the inner mitochondrial membrane as an
asymmetric homodimer [Leung et al., 2015]. We used the H-NNT
model to identify the homodimerization interface sites for domain
I. In order to construct the homodimer structure for H-NNT do-
main I, the E. coli domain I complex was used as a template (PDB:
2bru, dI2-dIII structure). Two monomeric chains of H-NNT were
superposed to the E. coli dimeric structure and rotated using the E.
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Figure 3. NADP ligand binding site. A: 3D structure of domain III in H-NNT. The NADP cleft is presented in green and NADP as blue
spheres. B: Schematic 2D representation of domain III residues interacting with NADP. The diagram was generated with Ligplot+ using the
human structure of domain III (PDB 1djl). The bold purple bonds belong to the ligand, whereas the thin brown bonds to H-NNT. Hydrogen
bonds between H-NNT and NADP are presented as dashed lines. H-NNT residues making hydrophobic contact are presented as spiked arcs.
C: Residues Ala1008 and Asn1009, which harbor variations p.Ala1008Pro and p.Asn1009Lys, interact with NADP. H-NNT residues have been
renumbered to follow NNT amino acid numbering reported in Uniprot. The alignment between PDB 1djl and H-NNT Uniprot sequence is available
at: http://www.ebi.ac.uk/thornton-srv/databases/cgi-bin/pdbsum/GetPage.pl?pdbcode=1djl&template=align.html&l=1.
coli complex coordinates. Superposition of equivalent domain I C
alpha atoms (r.m.s.d. = 0.80 A˚) between human and E. coli NNT,
demonstrated a high level of similarity betweenmodel and template.
As expected, manual comparative analysis showed that the highest
level of structural divergence was located within loop regions. The
model allowed calculation of the 3D atomic coordinates of residues
forming the domain I-domain I interface site for H-NNT. Residues
forming this large protein–protein interface and their conservation
score are reported in Figure 4. The majority of residues forming
the beta hairpin fold were shown to be part of this large interface
(Fig. 4A). Among these, Phe211, Gly212, Phe214, Phe215, Ala222,
and Ala228 were predicted to be interface core residues, as they
shifted from solvent accessible to fully buried (solvent inaccessible)
upon dimer formation. Identification of interface core residues is of
particular relevance, since they play a major role in protein-protein
interaction and binding affinity [Chakrabarti and Janin 2002] and
are a hot spot for disease causing variations [David et al., 2012].
Although mutational studies in E. coli have shown that deletion of
the beta hairpin does not impair the formation of domain I dimer
[Johansson et al., 2005], the interface residues, which are part of
the beta hairpin, could still play a role in modulating the affinity of
domain I dimer formation.
The NNT transmembrane domain (domain II) has been crystal-
lized as a dimer inT. thermophilus [Leung et al., 2015].We generated
the H-NNT domain II dimer using bacterial transhydrogenase 3D
coordinates as a template (PDB 4o9t, sequence identity 34%). Se-
quence and structural alignment showed that H-NNTTM2, 3 and 4
correspond to Tt-NNT TM1-2-3. Structural superposition between
model and template shows that several residues on opposite TM1s
in Tt-NNT and the equivalent TM2s in H-NNT can potentially take
part in hydrophobic interactions. Nevertheless, the presence of two
additional helices in theH-NNT(TM1andTM5,which couldnot be
modeleddue to the absenceof a suitable template) could result indif-
ferent placement of TM2within the innermitochondrialmembrane
and therefore a different role in domain II dimerization. Moreover,
participation of additional residues, located on TM1 and/or TM5,
to H-NNT domain II interface site cannot be excluded. A cartoon of
the E. coliNNTdomain II (which contains 13 TMhelices) generated
in 2001 based on literature data, suggests that TM1 may be located
next to TM2, thus in close proximity to domain II dimerization
site [Meuller et al., 2001]. Nevertheless, in this cartoon, the spatial
location of the helices surrounding the proton canal appears to be
different from what reported by Leung et al. using the solved struc-
ture of Tt-NNT [Leung et al., 2015]. In particular, TM4 appears not
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Figure 4. The predictedH-NNT domain I interface site and amino acid substitutions causing glucocorticoid deficiency.A: Surface representation
of the large interface site (in green) formed by two domain I monomers (presented in light and dark gray, respectively). The NAD binding sites,
one on each monomer, are presented in orange. B: Residue His365, which harbors the p.His365Pro substitution, is a rim interface residue and is
predicted to interact with Asp104 on the opposite domain I. C: Phe215, which harbors the p.Phe215Ser substitution, is a conserved interface core
residue. Phe215 is predicted to form stacking interactions with Phe211 on the same chain. The name (res) and position on the NNT amino acid
sequence (pos) of residues predicted to form the core and rim of dimer I interface is also presented.
to contribute to the hexagonal topology of the proton canal. Because
of this discrepancy, and in the absence of a solved structure for E.
coli domain II, it is difficult to speculate on the location of TM1 in
relation to other helices and to the dimerization site in H-NNT.
Sequence and structural analysis of NNT deleterious
variations
The availability of the H-NNT model allowed analysis of the
structural/functional consequences of deleterious NNT amino acid
substitutions and their predicted effect on H-NNT is detailed below
and in Table 2, Supp. Figure S1, and Supp. Figure S8A-Q.
p.Ser193Asn, homozygous in FGD patient [Meimaridou et al.,
2012]. Ser193 is an invariable residuepart of the enzymecatalytic site
of the proton-translocating transhydrogenase, which also involves
the invariable residues Arg182, Gln187, and Asp190 (Supp. Fig.
S5). Substitution of Ser138 in R. rubrum, which is equivalent to
Ser193 in H-NNT, leads to inhibition of the transhydrogenation
rate without changing the binding affinity of the transhydrogenase
to NAD [Brondijk et al., 2006].
p.Gly200Ser, homozygous in patients with combined mineralo-
corticoid and glucocorticoid deficiency [Weinberg-Shukron et al.,
2015]. Position 200 is an invariant Gly. It is located in an alpha helix,
tightly packed against the alpha helix of Rossmann fold in domain I.
Substitution ofGly to Ser is predicted to create a steric clashwith this
important structural motif. Moreover, this substitution introduces
a hydrophilic residue in an otherwise hydrophobic environment.
p.Phe215Ser, homozygous in FGD patient [Yamaguchi et al.,
2013]. Phe215 is a core residue of the dimerization interface of
domain I. It is at the beginning of the beta hairpin structural motif.
Phe215 stabilizes bacterial and human NNT structure by forming
a stacking interaction with Phe211 on the same chain (Fig. 4B).
Phe is a large, hydrophobic amino acid. Its substitution with ser-
ine would introduce a polar and much smaller amino acid, not
able to form stacking interactions. This substitution is predicted
to affect the H-NNT structure and in particular the dimerization
site.
p.Asp277Tyr, identified in a patient with left ventricular non-
compaction (LVNC, MIM#604169) [Bainbridge et al., 2015]. This
position is predicted to be part of a loop in domain I. The loop
in human NNT is longer than the corresponding loop in bacterial
transhydrogenase and therefore a structural analysis could not be
performed. Position 227 is not conserved, nevertheless tyrosine is
never observed in the MSA. This substitution is predicted to be
deleterious by prediction programs (Table 2) and functional stud-
ies demonstrated that it causes a partial loss in NNT function in
Zebrafish larvae [Bainbridge et al., 2015].
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Table 2. Conservation Score and Prediction Scores from Three Variant Prediction Servers for H-NNT Deleterious Amino Acid Substitu-
tions and Rare Genetic Variations Reported in the EXAC Database
Genetic variation Conservation score Most common amino acids in the alignment SIFT Polyphen2 Suspect Structural analysis Figure
p.Arg27His 1 Pro(50.0%), Arg(20.0%), Thr, Lys and His (10.0%) 0.13 T 0.000 T 24 T n.a. n.a.
p.Lys63Arg 4 Lys(77.8%), Arg(16.7%), Gln(5.6%) 0.47 T 0.895 Poss D 28 T Likely tolerated S Fig 8A
p.Ser193Asn 9 Ser(100.0%) 0 D 0.754 Poss D 60 D Likely deleterious S Fig 5
p.Gly200Ser 9 Gly(100.0%) 0.02 D 0.252 T 90 D Likely deleterious S Fig 8B
p.Phe215Ser 9 Phe(100.0%) 0 D 1.00 D 47 Poss D Likely deleterious S Fig 8C
p.Asp277Tyr 5 Asp(77.8%), Asn(16.7%), Pro(5.6%) 0 D 0.686 Poss D 62 D n.a. n.a.
p.Thr357Ala 8 Thr(88.9%), Ser(5.6%), Ile(5.6%) 0 D 0.204 T 75 D Likely deleterious S Fig 8D
p.His365Pro 1 His(61.1%), Val and Lys(11.1%), Tyr, Glu and Ala(5.6%) 0.27 T 0.915 Poss D 19 T Likely deleterious S Fig 8E
p.Tyr388Ser 7 Tyr(94.4%), Phe(5.6%) 0 D 1.00 D 85 D Likely deleterious S Fig 8F
p.Pro437Leu 7 Pro(94.4%), Gly(5.6%) 0 D 0.942 Poss D 77 D Likely deleterious S Fig 8G
p.Ala533Val 8 Ala(94.4%), Phe(5.6%) 0 D 0.986 D 80 D Likely deleterious S Fig 8H
p.Thr589Ser 2∗ Thr(62.5%), Asp(25.0%), Gln(6.3%), Pro(6.3%) 0.09 T 0.376 T 15 T n.a. n.a.
p.Leu663Phe 5 Gly(77.8%), Phe(11.1%), Val(5.6%), Leu(5.6%) 0.01 D 1.00 D 24 T Likely tolerated S Fig 8I
p.Gly664Arg 8 Gly(100.0%) 0 D 1.00 D 56 D Likely deleterious S Fig 8J
p.Gly678Arg 1 Gly(61.1%), Leu(22.2%), Thr, Ser and Ala(5.6%) 0.02 D 0.841 Poss D 56 D Likely deleterious S Fig 8K
p.Thr731Met 1 Thr(52.9%), Glu(23.5%), Ala(11.8%), Met and Leu(5.9%) 0.07 T 0.035 T 21 T Likely tolerated S Fig 8L
p.Gly862Asp 9 Gly(100.0%) 0 D 1.00 D 87 D Likely deleterious S Fig 8M
p.Leu977Pro 9 Leu(100.0%) 0 D 1.00 D 92 D Likely deleterious S Fig 8N
p.Ile993Val 9 Ile(94.4%), Leu(5.6%) 0.04 D 0.804 poss D 35 T Likely tolerated S Fig 8O
p.Ala1008Pro 9 Ala(94.4%), Ser(5.6%) 0 D 1.00 D 94 D Likely deleterious S Fig 8P
p.Asn1009Lys 9 Asn(100.0%) 0 D 1.00 D 84 D Likely deleterious S Fig 8Q
D, deleterious; Poss D, possibly deleterious; T, tolerated. Score is predicted deleterious if <0.05 for SIFT and 50 for Suspect. Polyphen2 calculates the naı¨ve Bayesian posterior
probability that a mutation is deleterious and classifies it accordingly, in “possibly” or “probably” deleterious or tolerated. ∗, unreliable estimate due to high number of gaps in
alignment. S Fig, Supp. Figure.
p.Thr357Ala, found in compound heterozygosity in an FGD
patient in addition to p.Met880Ter, which is predicted to cause
nonsense-mediated NNT mRNA decay [Meimaridou et al., 2012].
Thr357 is a hydrophilic, highly conserved residue on the surface of
bacterial and human NNT and participates in hydrogen bonding.
Its substitution with the hydrophobic alanine disrupts the H bond-
ing. This substitution is predicted damaging by SIFT and Suspect
(scores 0 and 75, respectively) but not by Polyphen2 (score = 0.204).
p.His365Pro, homozygous in an FGDpatient [Meimaridou et al.,
2012]. His365 is part of H-NNT domain I homodimerization site.
It is an interface rim residue. His365 is likely to form a salt bridge
with Asp104 on the other chain of the dimer (Fig. 4C). His365
is part of a loop and its substitution with proline is likely to be
structurally damaging, as it prevents formation of the salt bridge
and can introduce a rigid structure in an otherwise short flexible
motif. Interestingly, althoughHis365 andAsp104 are not conserved,
the salt bridge at this position is. InE. coli, a salt bridge can be formed
by residues Glu304 and Lys48 corresponding toHis365 and Asp104,
respectively. This substitution is predicted possibly damaging by
Polyphen2 but benign by SIFT and Suspect (Table 2).
p.Tyr388Ser, reported in a patient with combined adrenal fail-
ure and testicular adrenal rest tumor [Hershkovitz et al., 2015].
Tyr388 is located in domain I outside the NAD binding cleft and the
dimerization site. Tyr388 is likely to form a stacking interactionwith
Phe154, thus helping stabilizing the structure of domain I, similarly
to what is observed in bacterial NNT (Tyr327 and Phe92, respec-
tively). Substitution of tyrosine with serine is predicted to alter the
structural stability of domain I.
p.Pro437Leu, found in compound heterozygosity in an FGD
patient in addition to p.Gln557Ter, which is predicted to cause
nonsense-mediated NNT mRNA decay [Meimaridou et al., 2012].
Pro437 is part of the highly conserved amino acid sequence PAP in
the linker between domains I and II. Substitution with any other
amino acid is likely to be structurally and functionally damaging.
p.Ala533Val, homozygous in an FGD patient [Meimaridou et al.,
2012]. Ala553 is a highly conserved residue and contributes to the
formation of an alpha helix (TM3 in domain II). Substitution with
valine is predicted to cause structural damage, as valine is a poor
alpha helix forming residue [Gregoret and Sauer 1998]. Moreover,
substitution with valine is predicted to create a steric clash with the
surrounding residues.
p.Gly664Arg, found in compound heterozygosity in an FGD pa-
tient in addition top.Thr689LeufsTer320,which is predicted to cause
nonsense-mediated NNT mRNA decay [Meimaridou et al., 2012].
Gly664 is an evolutionarily conserved residue in TM7 of the NNT
transmembrane domain. This variation replaces the smallest in size,
hydrophobic, neutral residue with the largest in size, hydrophilic,
charged residue. These large physico-chemical changes are likely to
be structurally damaging, especially since this amino acid change
occurs in a hydrophobic environment.
p.Gly678Arg, found in a patient with FGD in compound
heterozygosity with the p.Gly862Asp change described below
[Meimaridou et al., 2012]. Gly678 is located in TM8 of the trans-
membrane domain. The MSA shows that Gly678 is not evolution-
arily conserved. Nevertheless, this position is generally occupied by
hydrophobic residues (valine, leucine, glycine, and alanine),which is
consistent with the hydrophobic environment in which this residue
is located. Similarly to the previous variation,Gly678Arg is therefore
predicted to be structurally damaging.
p.Gly862Asp Gly862 is an invariant residue located in the TM14
of the transmembrane domain. It is part of an alpha helix, which
is tightly packed with other TMs. Substitution between glycine and
aspartic acid introduces major physico-chemical changes (aspartic
acid is a charged, hydrophilic residue). Moreover, introduction of
aspartic acid is likely to create a steric clash with nearby TMs and,
thus, structural damaging.
p.Leu977Pro,homozygous in an FGDpatient [Meimaridou et al.,
2012]. Leu977 is a highly conserved residue, located in domain III,
outside the NAD binding site. Leu977 is part of an alpha helix
and its substitution with proline is predicted to cause a kink in
the alpha helix and loss of stability, causing structural damage to
domain III.
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Table 3. Rare Amino Acid Substitutions Identified in Homozygosity in the 1000Genomes Project
Protein consequence Transcript consequence Filter Annotation Allele count Allele number Number of homozygotes
p.Lys63Arg ENST00000264663.5:c.188A > G PASS Missense 5,565 121100 196
p.Leu663Phe ENST00000264663.5:c.1987C > T PASS Missense 5,425 121298 188
p.Ile993Val ENST00000264663.5:c.2977A > G PASS Missense 1,107 120944 7
p.Thr731Met ENST00000264663.5:c.2192C > T PASS Missense 897 121348 4
p.Arg27His ENST00000264663.5:c.80G > A PASS Missense 197 121362 2
p.Thr589Ser ENST00000264663.5:c.1765A > T PASS Missense 17 121412 1
p.Ala1008Pro and p.Asn1009Lys. Both variations were found
in patients with FGD: p.Ala1008Pro was present in homozygos-
ity, whereas p.Asn1009Lys was in compound heterozygosity with
p.His370Ter, which is predicted to cause nonsense-mediatedmRNA
decay [Meimaridou et al., 2012]. Ala1008 andAsn1009 are invariant
residues located at the NADP cleft in H-NNT domain III, directly
interacting with NADP (Fig. 3B and C). Substitution of these cru-
cial amino acids is predicted to alter NADP binding, thus, greatly
affecting H-NNT function.
Sequence and structural analysis of NNT rare SAVs
The following rare variants (detailed in Tables 2 and 3) have
been identified in homozygosity in the 1000 Genomes Project [1000
Genomes Project Consortium et al., 2015] and are reported in the
EXAC database [Consortium et al., 2015]:
p.Arg27His (rs34241095) Arg27 could not be mapped onto the
H-NNT structure. The initial 39 amino acids in H-NNTmay repre-
sent the mitochondrial targeting peptide. This short sequence is not
present in bacterial transhydrogenases. Position 27 is not conserved
and p.Arg27His is predicted benign by most prediction programs
(Polyphen2 = 0, SIFT = 0.13, Suspect = 24). Nevertheless, one pre-
diction program (TargetP) suggests that this substitutionmay affect
the mitochondrial targeting peptide. The latter has been shown to
be enriched in positively charged and hydroxylated residues, but
no clear consensus sequence is known to date [Habib et al., 2007].
Since the mitochondrial targeting peptide is not well characterized,
it is not possible to make a prediction on the neutral or deleterious
nature of this amino acid change.
p.Lys63Arg (rs35201656) Lys63 is a positive surface amino acid.
The position in not conserved and can be occupied by arginine
(Supp. Table S2). Lys63 is neither in domain I dimerization site, nor
in proximity to NAD binding site. The p.Lys63Arg substitution is
likely to be tolerated (SIFT = 0.47 tolerated, Suspect = 28 tolerated,
Polyphen2 = 0.895 damaging).
p.Thr589Ser (rs370370846) Thr589 is part of a loop located in
the mitochondrial matrix between helices TM4 and TM5. The loop
in human NNT is longer than the corresponding loop in bacterial
transhydrogenase. This position was not modeled in the H-NNT
model and could not be structurally analyzed. Threonine and serine
have similar chemical properties (polar, non-charged, and capable
of forming hydrogen bonds) and are often interchangeable. Threo-
nine to serine substitution is predicted tolerated by most programs
(Polyphen2 = 0.376 tolerated, SIFT = 0.09 tolerated, Suspect = 15
tolerated).
p.Leu663Phe (rs41271083) Leu663 is in the TM7 alpha helix of
the transmembrane domain. Its substitution with phenylalanine is
predicted damaging (Polyphen2 = 1 damaging, SIFT = 0.01 dam-
aging, Suspect = 24 tolerated). Nevertheless, leucine and phenylala-
nine are amino acidswith similar chemical properties (hydrophobic,
not charged amino acids) and the MSA shows that, although this
position is generally occupied by leucine, other residues such as
isoleucine and phenylalanine, can also be present (Supp. Table S2).
The lack of all 14 TM helices in the H-NNT model does not allow
excluding that this substitution could affect packing of TM7 with
TM1 or TM5 in H-NNT.
p.Thr731Met (rs75710404) Thr731 is part of a loop located in
the intermembrane mitochondrial space between helices TM9 and
TM10 and it is unlikely to cause any structural damage. Methionine
can be found at this position in the MSA and the threonine to
methionine substitution is predicted benign by prediction programs
(Polyphen2 = 0.035 tolerated, SIFT = 0.07 tolerated, Suspect = 21
tolerated).
p.Ile993Val (rs78818665) Ile993 is located within an alpha he-
lix in domain III. It is not in proximity to the NADP cleft and
its substitution is not predicted to affect NADP binding. Two
prediction programs predict this substitution to be not tolerated
(Polyphen2 = 0.804 possibly damaging, SIFT = 0.04 damaging, Sus-
pect = 35 tolerated). Nevertheless, isoleucine and valine have similar
chemical properties and valine can be seen, although rarely, at this
position in the MSA.
Discussion
This study describes the first structuralmodel of the humanNNT,
an enzyme crucial in the defence of cells against oxidative stress,
defects in which have not only been linked to FGD and LVNC,
but are also strong candidates for several other human disorders
[Freeman et al., 2006; Reuter et al., 2010; Ripoll et al., 2012]. The 3D
model was used to identify functional and structural H-NNT key
motifs and gain essential insight into the structural and functional
effect of deleterious amino acid substitutions causing glucocorticoid
deficiency and LVNC cardiomyopathy, as well as rare homozygote
amino acid variations.
NNT is widely expressed and is likely to contribute to the patho-
genesis of a wide range of medical conditions ranging from ag-
ing to cancer [Uttara et al., 2009; Reuter et al., 2010]. Therefore,
identification of residues, which represent susceptible positions for
disease-causing variations, is important. Although amino acid evo-
lutionary conservation is a good indicator of the structural and
functional importance of residues, it cannot inform us on the ef-
fects of amino acid substitutions on a biological system. One fourth
of amino acid variations in the human genome are predicted to be
deleterious by themost widely SAV prediction tools [Yue andMoult
2006; Allali-Hassani et al., 2009; Adzhubei et al., 2010]. As an amino
acid substitution may alter protein fitness by affecting its folding,
its location within the cell, its interaction with other molecules, or
its ligand binding and catalytic activity [Yates and Sternberg 2013;
Stefl et al., 2013], additional methods are required for informing
SAV prioritization.
Individual transhydrogenase domains as well as the domain I–
domain III complex have been determined in bacteria [Bergkvist
et al., 2000; Prasad et al., 2002] andbovineNNT[Prasad et al., 1999].
Availability of 3D structures for individual domains and complexes
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allowed us to generate a model for H-NNT and to demonstrate how
amino acid substitutions affectH-NNTfitness through awide range
of functional and structural mechanisms.
Without the H-NNT 3D model, molecular mechanisms
could only be identified for two variations (p.Ala1008Pro and
p.Asn1009Lys), which are located in the NADP binding site. The H-
NNT 3D model allowed predictions of residues forming the NAD
cleft. This would not have been possible without the aid of a 3D
model. As NNT has a crucial role in the redox process, characteri-
zation of the NAD cleft becomes of paramount importance toward
the understanding of NNT function and to guide in vitro studies.
Knowledge of the residues predicted to form the NAD cleft also
allowed characterization of variations, such as Ser193Asn.
Another important example of the importance of H-NNT 3D
model was the ability to identify domain I interface site. Disruption
of protein–protein interaction, which includes the proteins ability
to dimerize, has been recently demonstrated to be an important
mechanism in human disease [David et al., 2012; Nishi et al., 2013;
Das et al., 2014].We showed that H-NNTdimer has a large interface
region and at least two NNT variations may affect NNT function by
altering its dimerization site. In particular, we dissected the domain
I interface into “core” and “rim” residues. Core residues are of
great importance in establishing and maintaining protein–protein
interaction and their substitution is unlikely to be tolerated [David
and Sternberg 2015], as in the case of p.Phe215Ser.
Another important mechanism by which deleterious amino acid
substitutions impair NNT function is the disruption of its ability to
correctly fold within the mitochondrial inner membrane. This was
likely to be the case for three variations in domain II (p.Gly664Arg,
p.Gly678Arg, and p.Gly862Asp). We predicted that these substitu-
tions would alter the “groove-hinge” system, which represents the
basis for transmembrane helices packing.
A crucial feature of NNT is the ability of domain III to flip ac-
cording to NNT functional state (proton translocation across the
membrane or hydrogen transfer). [Leung et al. 2015] demonstrated
in the structure of bacterial transhydrogenase (which is localized
in the cytosol) that domain III cycles from an up-face orientation
(NADP binding site oriented toward domain I and interacting with
NAD binding site) to a face down orientation (NADP binding site
oriented toward domain II, thus away from NAD binding site). The
opposite phenomenon would occur in the second monomer, thus
conferring an asymmetric structure to the NNT dimer. Moreover,
they proposed that different orientation of domain III are associated
with modifications in domain II proton canal orientation (inward
or outward facing) and its ability to translocate protons across the
mitochondrial membrane. The high level of structural similarity
between the bacterial transhydrogenase structure and the human
NNT model, suggests that the same mechanism is likely to occur
in the human NNT dimer, as previously suggested [Krengel and
To¨rnroth-Horsefield 2015].
The flipping of domain III requires the absence of a rigid struc-
ture in the linker between domain II and III. Our structural analysis
reveals that the amino acid sequence of this linker is highly dis-
ordered, thus supporting the hypothesis that this region is highly
flexible. Identificationof the amino acid sequence forming the linker
in human NNT would not have been possible without the availabil-
ity of a 3D model. Moreover, understanding the physical properties
of the linker is of particular importance when analyzing amino acid
substitution occurring in this region. There is mounting evidence
of the role of intrinsically disorder regions (IDRs) in human disease
[Uversky et al., 2008]. Amino acid substitutions occurring in the
hinge should be evaluated for their propensity to create a disorder-
to-order transition, which would affect the hinge flexibility, as it is
often the case in deleterious mutations occurring in IDRs [Dunker
et al., 2008]. Although at the moment no NNT deleterious varia-
tions are known to occur in this region, identifications of potentially
deleterious amino acid substitutions in the hinge may occur in the
future.
In conclusion, structural biology can provide valuable informa-
tion on protein structure–function relationship and integration of
genetic analysiswithprotein3Dmodeling cangreatly enhanceprior-
itization and interpretation of genetic variants. Analysis of H-NNT
3Dmodel and structural interpretation of its deleterious amino acid
substitutions, represent a powerful example. Moreover, availability
of H-NNT 3Dmodel and identification of key structural/functional
residues will prove valuable, as several novel NNT genetic variations
are likely to be identified in the near future, not only as a cause of
adrenal disorders, but as a risk factor for a wide range of conditions,
such as aging, inflammatory response, and cancer.
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